Meeder Asset Management’s Acorda Therapeutics ACOR Stock Holding History

Meeder Asset Management’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-22	Closed	-$7K	–	2465
2019 Q3	$7K	Buy	22 +15	+214%	+$8.15K	﹤0.01%	1672
2019 Q2	$7K	Hold	7	–	–	﹤0.01%	1583
2019 Q1	$12K	Sell	7 -93	-93%	-$168K	﹤0.01%	1207
2018 Q4	$188K	Buy	100 +26	+35%	+$56.6K	0.02%	512
2018 Q3	$176K	Buy	74 +67	+957%	+$207K	0.01%	520
2018 Q2	$25.6K	Sell	7 -3	-30%	-$9.19K	﹤0.01%	909
2018 Q1	$29K	Sell	10 -5	-33%	-$15K	﹤0.01%	797
2017 Q4	$40K	Buy	15 +8	+114%	+$22.7K	﹤0.01%	741
2017 Q3	$19K	Hold	7	–	–	﹤0.01%	918
2017 Q2	$16K	Buy	7 +6	+600%	+$11.9K	﹤0.01%	880
2017 Q1	$3K	Buy	+1	New	+$2.88K	﹤0.01%	1293
2016 Q3	–	Sell	-19	Closed	-$58K	–	987
2016 Q2	$58K	Buy	+19	New	+$61.8K	0.01%	713

Other funds holding ACOR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Meeder Asset Management's ACOR Position: Q4 2019 in Review

Meeder Asset Management sold out of Acorda Therapeutics (ACOR) in Q4 2019, closing a stake of 22 shares — an estimated $7K sold.

Meeder Asset Management first reported a position in ACOR in Q2 2016 and held it in 12 quarters. The position peaked at $188K in Q4 2018. 121 funds tracked by Wall St. Rank hold ACOR as of Q4 2019.

Meeder Asset Management reported no remaining Acorda Therapeutics position as of Q4 2019 after selling out during the quarter.
Meeder Asset Management sold 22 Acorda Therapeutics shares in Q4 2019, an estimated $7K.
Meeder Asset Management first reported a position in Acorda Therapeutics in Q2 2016 and held it in 12 quarters.
Meeder Asset Management's Acorda Therapeutics position peaked at $188K in Q4 2018.
121 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2019.

Based on Meeder Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.